학술논문
Evaluation of Time to Onset and Outcome of Lung Adverse Events Related to Pembrolizumab Using Marketing Surveillance
Document Type
Article
Author
Source
In: Oncology (Switzerland) . (Oncology (Switzerland), 17 August 2023, 101(12):817-821)
Subject
Language
English
ISSN
14230232
00302414
00302414